INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $4,535,000 | +0.4% | 5,000,000 | 0.0% | 0.02% | -4.8% |
| Q2 2021 | $4,519,000 | +9.3% | 5,000,000 | 0.0% | 0.02% | -8.7% |
| Q1 2021 | $4,136,000 | +4.0% | 5,000,000 | 0.0% | 0.02% | 0.0% |
| Q4 2020 | $3,977,000 | -1.5% | 5,000,000 | 0.0% | 0.02% | -11.5% |
| Q3 2020 | $4,037,000 | +7.3% | 5,000,000 | 0.0% | 0.03% | -3.7% |
| Q2 2020 | $3,763,000 | -7.6% | 5,000,000 | 0.0% | 0.03% | -15.6% |
| Q1 2020 | $4,072,000 | -19.3% | 5,000,000 | 0.0% | 0.03% | +28.0% |
| Q4 2019 | $5,047,000 | +17.3% | 5,000,000 | 0.0% | 0.02% | +8.7% |
| Q3 2019 | $4,301,000 | -3.5% | 5,000,000 | 0.0% | 0.02% | -8.0% |
| Q2 2019 | $4,456,000 | -10.2% | 5,000,000 | 0.0% | 0.02% | -19.4% |
| Q1 2019 | $4,960,000 | +7.3% | 5,000,000 | 0.0% | 0.03% | 0.0% |
| Q4 2018 | $4,624,000 | -8.3% | 5,000,000 | 0.0% | 0.03% | +10.7% |
| Q3 2018 | $5,044,000 | +14.7% | 5,000,000 | 0.0% | 0.03% | +3.7% |
| Q2 2018 | $4,396,000 | +8.9% | 5,000,000 | 0.0% | 0.03% | +3.8% |
| Q1 2018 | $4,038,000 | +0.1% | 5,000,000 | 0.0% | 0.03% | +23.8% |
| Q4 2017 | $4,033,000 | +3.4% | 5,000,000 | 0.0% | 0.02% | -30.0% |
| Q3 2017 | $3,900,000 | -20.3% | 5,000,000 | 0.0% | 0.03% | -16.7% |
| Q2 2017 | $4,895,000 | +5.0% | 5,000,000 | 0.0% | 0.04% | -2.7% |
| Q1 2017 | $4,660,000 | +4.3% | 5,000,000 | 0.0% | 0.04% | +2.8% |
| Q4 2016 | $4,468,000 | -20.3% | 5,000,000 | 0.0% | 0.04% | -10.0% |
| Q3 2016 | $5,603,000 | – | 5,000,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|